ZAI LAB LIMITED Share-based Payment Arrangement, Expense
ZAI LAB LIMITED (ZLAB) reported Share-based Payment Arrangement, Expense of $12.13 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AllocatedShareBasedCompensationExpense · last filed 2026-08-06
- ZAI LAB LIMITED share-based payment arrangement, expense for the quarter ending 2026-06-30 was $12.13M, a 28.56% decline year-over-year.
- ZAI LAB LIMITED share-based payment arrangement, expense for the quarter ending 2026-03-31 was $13.56M, a 14.15% decline year-over-year.
- ZAI LAB LIMITED share-based payment arrangement, expense for the quarter ending 2025-12-31 was $15.90M, a 7.75% decline year-over-year.
- ZAI LAB LIMITED share-based payment arrangement, expense for the quarter ending 2025-09-30 was $16.92M, a 0.76% increase year-over-year.
- ZAI LAB LIMITED share-based payment arrangement, expense for fiscal 2025 was $65.60M, a 7.15% decline from fiscal 2024.
- ZAI LAB LIMITED share-based payment arrangement, expense for fiscal 2024 was $70.65M, a 11.28% decline from fiscal 2023.
- ZAI LAB LIMITED share-based payment arrangement, expense for fiscal 2023 was $79.63M, a 29.90% increase from fiscal 2022.
- ZAI LAB LIMITED share-based payment arrangement, expense for fiscal 2022 was $61.30M, a 50.57% increase from fiscal 2021.
| Period end | Share-based Payment Arrangement, Expense 3 month | Share-based Payment Arrangement, Expense 6 month | Share-based Payment Arrangement, Expense 9 month | Share-based Payment Arrangement, Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $12.13M 10-Q · filed 2026-08-06 | $25.69M 10-Q · filed 2026-08-06 | $41.59M derived: sum of 3 quarters · filed 2026-08-06 | $58.52M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $13.56M 10-Q · filed 2026-05-07 | $29.47M derived: sum of 2 quarters · filed 2026-05-07 | $46.39M derived: sum of 3 quarters · filed 2026-05-07 | $63.36M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $15.90M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $32.83M derived: sum of 2 quarters · filed 2026-02-26 | $49.80M derived: sum of 3 quarters · filed 2026-08-06 | $65.60M 10-K · filed 2026-02-26 |
| 2025-09-30 | $16.92M 10-Q · filed 2025-11-06 | $33.90M derived: sum of 2 quarters · filed 2026-08-06 | $49.70M 10-Q · filed 2025-11-06 | $66.93M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $16.97M 10-Q · filed 2026-08-06 | $32.77M 10-Q · filed 2026-08-06 | $50.01M derived: sum of 3 quarters · filed 2026-08-06 | $66.81M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $15.80M 10-Q · filed 2026-05-07 | $33.04M derived: sum of 2 quarters · filed 2026-05-07 | $49.83M derived: sum of 3 quarters · filed 2026-05-07 | $68.47M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $17.24M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $34.03M derived: sum of 2 quarters · filed 2026-02-26 | $52.67M derived: sum of 3 quarters · filed 2026-02-26 | $70.65M 10-K · filed 2026-02-26 |
| 2024-09-30 | $16.80M 10-Q · filed 2025-11-06 | $35.43M derived: sum of 2 quarters · filed 2025-11-06 | $53.41M 10-Q · filed 2025-11-06 | $73.88M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $18.64M 10-Q · filed 2025-08-07 | $36.62M 10-Q · filed 2025-08-07 | $57.09M derived: sum of 3 quarters · filed 2026-02-26 | $79.08M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $17.98M 10-Q · filed 2025-05-08 | $38.45M derived: sum of 2 quarters · filed 2026-02-26 | $60.44M derived: sum of 3 quarters · filed 2026-02-26 | $80.95M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $20.47M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $42.46M derived: sum of 2 quarters · filed 2026-02-26 | $62.97M derived: sum of 3 quarters · filed 2026-02-26 | $79.63M 10-K · filed 2026-02-26 |
| 2023-09-30 | $21.99M 10-Q · filed 2024-11-12 | $42.50M derived: sum of 2 quarters · filed 2024-11-12 | $59.16M 10-Q · filed 2024-11-12 | $74.72M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | $20.51M 10-Q · filed 2024-08-06 | $37.17M 10-Q · filed 2024-08-06 | $52.73M derived: sum of 3 quarters · filed 2025-02-27 | $71.84M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | $16.66M 10-Q · filed 2024-05-08 | $32.22M derived: sum of 2 quarters · filed 2025-02-27 | $51.33M derived: sum of 3 quarters · filed 2025-02-27 | $65.55M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | $15.56M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $34.67M derived: sum of 2 quarters · filed 2025-02-27 | $48.89M derived: sum of 3 quarters · filed 2025-02-27 | $61.30M 10-K · filed 2025-02-27 |
| 2022-09-30 | $19.11M 10-Q · filed 2023-11-07 | $33.33M derived: sum of 2 quarters · filed 2023-11-07 | $45.74M 10-Q · filed 2023-11-07 | $58.35M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-06-30 | $14.22M 10-Q · filed 2023-08-07 | $26.64M 10-Q · filed 2023-08-07 | $39.24M derived: sum of 3 quarters · filed 2024-02-27 | $49.80M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-03-31 | $12.41M 10-Q · filed 2023-05-09 | $25.02M derived: sum of 2 quarters · filed 2024-02-27 | $35.57M derived: sum of 3 quarters · filed 2024-02-27 | $45.81M derived: sum of 4 quarters · filed 2024-02-27 |
| 2021-12-31 | $12.61M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $23.16M derived: sum of 2 quarters · filed 2024-02-27 | $33.40M derived: sum of 3 quarters · filed 2024-02-27 | $40.71M 10-K · filed 2024-02-27 |
| 2021-09-30 | $10.56M 10-Q · filed 2022-11-09 | $20.79M derived: sum of 2 quarters · filed 2022-11-09 | $28.11M 10-Q · filed 2022-11-09 | |
| 2021-06-30 | $10.23M 10-Q · filed 2022-08-09 | $17.55M 10-Q · filed 2022-08-09 | ||
| 2020-12-31 | $24.83M 10-K · filed 2023-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |